Regimen deemed ‘safe and feasible’ in MM

Print Friendly, PDF & Email


Keren Osman, MD
A novel transplant regimen is “safe and feasible” for patients with multiple myeloma (MM), according to a presentation at the 2018 BMT Tandem Meetings. Researchers conducted a phase 1 trial investigating the addition of elotuzumab and autologous peripheral blood mononuclear cell (PBMC) reconstitution to standard autologous hematopoietic stem cell transplant... [Read Article]
Print Friendly, PDF & Email

Drug receives orphan designation for MM

Print Friendly, PDF & Email


Bone marrow aspirate
showing MM
The US Food and Drug Administration (FDA) has granted orphan designation to PT-112 as a treatment for multiple myeloma (MM). PT-112 is a small-molecule conjugate of pyrophosphate and platinum that promotes apoptosis with damage-associated molecular patterns, leading to downstream T-cell recruitment in the tumor microenvironment. PT-112 is... [Read Article]
Print Friendly, PDF & Email

Agent can decrease GI toxicity in MM patients

Print Friendly, PDF & Email


HSCT preparation
Photo by Chad McNeeley
Results of a case-control study suggest a cytoprotective agent can reduce treatment-related gastrointestinal (GI) toxicity in patients with multiple myeloma (MM). Use of this agent, amifostine, was associated with significantly lower rates of grade 2 or higher oral mucositis, nausea, vomiting, and diarrhea. Additionally, amifostine did not... [Read Article]
Print Friendly, PDF & Email

Phototherapeutic technology could fight MM, other cancers

Print Friendly, PDF & Email


Samuel Achilefu, PhD
Photo courtesy of
Washington University
Preclinical research suggests that light-triggered, chemotherapy-loaded nanoparticles could treat multiple myeloma (MM) and other malignancies. Researchers showed that light emitted as part of traditional cancer-imaging techniques could also trigger a light-sensitive chemotherapy drug. When this drug was packaged into nanoparticles that target lit-up cancer cells,... [Read Article]
Print Friendly, PDF & Email

FDA clears assay for myeloma patients

Print Friendly, PDF & Email


Daratumumab (Darzalex)
Photo courtesy of Janssen
The US Food and Drug Administration (FDA) has granted 510(k) clearance for Sebia’s Hydrashift 2/4 daratumumab immunofixation assay. This in vitro diagnostic test allows for assessment of response in patients with multiple myeloma by mitigating potential interference caused by the anti-CD38 antibody daratumumab (Darzalex®). Daratumumab can interfere... [Read Article]
Print Friendly, PDF & Email